MX352074B - Derivados de 5-bencilaminometil-6-aminopirazolo [3,4-b] piridina como inhibidores de proteina de transferencia de ester de colesterilo (cetp) utiles para el tratamiento de aterosclerosis. - Google Patents

Derivados de 5-bencilaminometil-6-aminopirazolo [3,4-b] piridina como inhibidores de proteina de transferencia de ester de colesterilo (cetp) utiles para el tratamiento de aterosclerosis.

Info

Publication number
MX352074B
MX352074B MX2014003660A MX2014003660A MX352074B MX 352074 B MX352074 B MX 352074B MX 2014003660 A MX2014003660 A MX 2014003660A MX 2014003660 A MX2014003660 A MX 2014003660A MX 352074 B MX352074 B MX 352074B
Authority
MX
Mexico
Prior art keywords
cetp
benzylaminomethyl
aminopyrazolo
atherosclerosis
treatment
Prior art date
Application number
MX2014003660A
Other languages
English (en)
Spanish (es)
Other versions
MX2014003660A (es
Inventor
Boruah Anima
Alikunju Shanavas
Original Assignee
Dr Reddys Laboratories Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Dr Reddys Laboratories Ltd filed Critical Dr Reddys Laboratories Ltd
Publication of MX2014003660A publication Critical patent/MX2014003660A/es
Publication of MX352074B publication Critical patent/MX352074B/es

Links

Classifications

    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D471/00Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/02Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
    • C07D471/04Ortho-condensed systems
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/4353Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems
    • A61K31/437Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems the heterocyclic ring system containing a five-membered ring having nitrogen as a ring hetero atom, e.g. indolizine, beta-carboline
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47Quinolines; Isoquinolines
    • A61K31/4738Quinolines; Isoquinolines ortho- or peri-condensed with heterocyclic ring systems
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/506Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim not condensed and containing further heterocyclic rings
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00Drugs for disorders of the metabolism
    • A61P3/06Antihyperlipidemics
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00Drugs for disorders of the cardiovascular system
    • A61P9/10Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D401/00Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/12Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D403/00Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/02Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
    • C07D403/12Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings linked by a chain containing hetero atoms as chain links

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Epidemiology (AREA)
  • Vascular Medicine (AREA)
  • Urology & Nephrology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Cardiology (AREA)
  • Diabetes (AREA)
  • Hematology (AREA)
  • Obesity (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
MX2014003660A 2011-09-27 2012-09-27 Derivados de 5-bencilaminometil-6-aminopirazolo [3,4-b] piridina como inhibidores de proteina de transferencia de ester de colesterilo (cetp) utiles para el tratamiento de aterosclerosis. MX352074B (es)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
IN3337CH2011 2011-09-27
US201161558262P 2011-11-10 2011-11-10
PCT/IB2012/002435 WO2013046045A1 (en) 2011-09-27 2012-09-27 5 - benzylaminomethyl - 6 - aminopyrazolo [3, 4 -b] pyridine derivatives as cholesteryl ester -transfer protein (cetp) inhibitors useful for the treatment of atherosclerosis

Publications (2)

Publication Number Publication Date
MX2014003660A MX2014003660A (es) 2014-10-17
MX352074B true MX352074B (es) 2017-11-08

Family

ID=47994351

Family Applications (1)

Application Number Title Priority Date Filing Date
MX2014003660A MX352074B (es) 2011-09-27 2012-09-27 Derivados de 5-bencilaminometil-6-aminopirazolo [3,4-b] piridina como inhibidores de proteina de transferencia de ester de colesterilo (cetp) utiles para el tratamiento de aterosclerosis.

Country Status (11)

Country Link
US (1) US9000007B2 (cg-RX-API-DMAC7.html)
EP (1) EP2760864B1 (cg-RX-API-DMAC7.html)
JP (1) JP6140168B2 (cg-RX-API-DMAC7.html)
KR (1) KR101803866B1 (cg-RX-API-DMAC7.html)
CN (1) CN103958511A (cg-RX-API-DMAC7.html)
AU (1) AU2012313971B2 (cg-RX-API-DMAC7.html)
CA (1) CA2850022C (cg-RX-API-DMAC7.html)
HK (1) HK1197238A1 (cg-RX-API-DMAC7.html)
IN (1) IN2014CN02290A (cg-RX-API-DMAC7.html)
MX (1) MX352074B (cg-RX-API-DMAC7.html)
WO (1) WO2013046045A1 (cg-RX-API-DMAC7.html)

Families Citing this family (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP3081864B2 (ja) 1996-01-08 2000-08-28 三井化学株式会社 金属製接続部材付き合成樹脂製管継手及びその製造方法
JPWO2014017569A1 (ja) * 2012-07-26 2016-07-11 興和株式会社 血中ldlを低下させるための医薬
JP2015054838A (ja) * 2013-09-12 2015-03-23 興和株式会社 血中ldlコレステロールを低下させる医薬
JP6465813B2 (ja) * 2013-12-13 2019-02-06 第一三共株式会社 5−ヒドロキシ−4−(トリフルオロメチル)ピラゾロピリジン誘導体
CN109956940A (zh) * 2019-05-14 2019-07-02 上海贤鼎生物科技有限公司 一种帕博昔布中间体氰基化反应制备杂芳基氰化物的方法

Family Cites Families (105)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US2965643A (en) 1960-12-20 Derivatives of pyrazolo
US2858309A (en) 1956-05-07 1958-10-28 Ciba Pharm Prod Inc New aminobenzene sulfonamide
US3546295A (en) 1968-08-01 1970-12-08 Exxon Research Engineering Co N-cycloalkyl anilines
DE3143016A1 (de) 1980-10-29 1982-05-27 Nippon Kayaku K.K., Tokyo 5,6,7,8-tetrahydro-1,6-naphthyridinderivate und verfahren zu ihrer herstellung
JPH01104052A (ja) 1987-06-12 1989-04-21 Yoshitomi Pharmaceut Ind Ltd ピリジン誘導体
ES2058288T3 (es) 1987-07-08 1994-11-01 American Home Prod Composiciones de ibuprofen secadas por atomizacion.
US5474989A (en) 1988-11-11 1995-12-12 Kurita Water Industries, Ltd. Drug composition
US5260331A (en) 1989-01-02 1993-11-09 John Wyeth & Brother Limited Composition for treating depression with (S- or O-heteroaryl)alkyl amines
AU641394B2 (en) 1989-06-02 1993-09-23 John Wyeth & Brother Limited Amines
US5422355A (en) 1989-06-02 1995-06-06 John Wyeth & Brother, Limited Composition for treating depression with (N-heteroaryl)alkylamines
WO1992018106A1 (fr) 1991-04-16 1992-10-29 Nippon Shinyaku Co., Ltd. Procede de production d'une dispersion solide
US5348953A (en) 1991-06-25 1994-09-20 Merck & Co., Inc. Substituted azetidinones as anti-inflammatory and antidegenerative agents
WO1993000332A1 (en) 1991-06-25 1993-01-07 Merck & Co., Inc. Substituted azetidinones as anti-inflammatory and antidegenerative agents
TW225469B (cg-RX-API-DMAC7.html) 1991-11-12 1994-06-21 Nissan Kagakl Kogyo
FR2686339B1 (fr) 1992-01-22 1994-03-11 Adir Cie Nouveaux amides et sulfonamides naphtaleniques, leurs procedes de preparation et les compositions pharmaceutiques qui les contiennent.
EP0585500A1 (en) 1992-09-04 1994-03-09 Merrell Dow Pharmaceuticals Inc. Diaryl piperazineacetamides as antimuscarinic agents
NO179904C (no) 1992-09-04 1997-01-08 Takeda Chemical Industries Ltd Kondenserte heterocykliske forbindelser og deres anvendelse
MY131441A (en) 1992-12-29 2007-08-30 American Cyanamid Co Amidrazones and their use as insecticidal and acaricidal agents
DE69432019T2 (de) 1993-08-12 2003-11-27 Astrazeneca Ab, Soedertaelje Amidin-derivate mit stickstoffoxid-synthease-aktivität
US5491152A (en) 1994-03-23 1996-02-13 The Du Pont Merck Pharmaceutical Company Derivatives of cyclic ethers and sulfides for the treatment of atherosclerosis
JPH07285962A (ja) 1994-04-20 1995-10-31 Nissan Chem Ind Ltd ピリジンカルボン酸アミド誘導体
IT1270615B (it) 1994-07-14 1997-05-07 Smithkline Beecham Farma Uso di derivati di chinolina
JPH0892224A (ja) 1994-09-16 1996-04-09 Kumiai Chem Ind Co Ltd 3,5−置換フェニルトリアゾール誘導体および殺虫、殺ダニ剤
JPH0892225A (ja) 1994-09-29 1996-04-09 Nissan Chem Ind Ltd トリアゾールグリコール酸アミド誘導体
EP0790057B1 (en) 1994-11-29 2002-06-05 Hisamitsu Pharmaceutical Co., Inc. Antibacterial or bactericide comprising 2-aminothiazole derivative and salts thereof
GB9511220D0 (en) 1995-06-02 1995-07-26 Glaxo Group Ltd Solid dispersions
US6730679B1 (en) 1996-03-22 2004-05-04 Smithkline Beecham Corporation Pharmaceutical formulations
DE19615262A1 (de) 1996-04-18 1997-10-23 Bayer Ag Heteroverknüpfte Phenylglycinolamide
IL124935A (en) 1996-05-20 2001-06-14 Janssen Pharmaceutica Nv Dispersible antifungal compositions comprising itraconazole with improved bioavailability
AR008789A1 (es) 1996-07-31 2000-02-23 Bayer Corp Piridinas y bifenilos substituidos
DE19636150A1 (de) 1996-09-06 1998-03-12 Asta Medica Ag N-substituierte Indol-3-glyoxylamide mit antiasthmatischer, antiallergischer und immunsuppressiver/immunmodulierender Wirkung
TW523506B (en) 1996-12-18 2003-03-11 Ono Pharmaceutical Co Sulfonamide or carbamide derivatives and drugs containing the same as active ingredients
WO1998057928A1 (en) 1997-06-16 1998-12-23 American Home Products Corporation Elevation of hdl cholesterol by 2-(4-chloro -1-aryl-butylidene) -hydrazinecarbothioamides
US5977170A (en) 1997-06-16 1999-11-02 American Home Products Corporation Elevation of HDL cholesterol by 4-[(aminothioxomethyl)hydrazono]-4-arylbutyl carbamates
AU7589498A (en) 1997-06-16 1999-01-04 American Home Products Corporation Elevation of hdl cholesterol by 4-{(aminothioxomethyl)hydrazono}-4-arylbutyl carbamates
AU7688398A (en) 1997-06-16 1999-01-04 American Home Products Corporation Elevation of hdl cholesterol by 2-{(aminothioxomethyl)-hydrazono}-2-arylethyl carbamates
US6008362A (en) 1997-06-16 1999-12-28 Commons; Thomas Joseph Elevation of HDL cholesterol by 2-(-4-chlorol-1-aryl-butylidene)-hydrazinecarbothioamides
EP1745774A3 (en) 1997-08-11 2007-04-11 Pfizer Products Inc. Solid pharmaceutical dispersions with enhanced bioavailability
UA67754C2 (uk) 1997-10-10 2004-07-15 Пфайзер, Інк. Агоністи простагландину, фармацевтична композиція на їх основі (варіанти), спосіб нарощення та збереження кісткової маси у хребетних та спосіб лікування (варіанти)
JPH11209366A (ja) 1998-01-23 1999-08-03 Nissan Chem Ind Ltd クロマン誘導体及び心不全治療薬
DE19814838C2 (de) 1998-04-02 2001-01-18 Asta Medica Ag Indolyl-3-glyoxylsäure-Derivate mit Antitumorwirkung
US6121271A (en) 1998-05-12 2000-09-19 American Home Products Corporation Naphtho[2,3-B]heteroar-4-yl derivatives
GT199900147A (es) 1998-09-17 1999-09-06 1, 2, 3, 4- tetrahidroquinolinas 2-sustituidas 4-amino sustituidas.
US6350786B1 (en) 1998-09-22 2002-02-26 Hoffmann-La Roche Inc. Stable complexes of poorly soluble compounds in ionic polymers
DE19845202A1 (de) 1998-10-01 2000-04-06 Wella Ag Haarwuchsmittel
JP2002531515A (ja) 1998-12-11 2002-09-24 ファーマソリューションズ・インコーポレイテッド 水に難溶性の薬剤のための自己乳化組成物
EP1027885B1 (en) 1999-02-09 2008-07-09 Pfizer Products Inc. Basic drug compositions with enhanced bioavailability
RU2238264C2 (ru) 1999-02-24 2004-10-20 Ф.Хоффманн-Ля Рош Аг Производные бензола или пиридина и фармацевтическая композиция на их основе
HU228645B1 (en) 1999-06-23 2013-04-29 Syngenta Participations Ag Method of producing nitroguanidine and nitroenamine derivatives
DE19930075A1 (de) 1999-06-30 2001-01-04 Bayer Ag Neue Amino- und Amidosulfonamide als antivirale Mittel
US6451830B1 (en) 1999-09-23 2002-09-17 G.D. Searle & Co. Use of substituted N,N-disubstituted non-fused heterocyclo amino compounds for inhibiting cholesteryl ester transfer protein activity
TWI269654B (en) 1999-09-28 2007-01-01 Baxter Healthcare Sa N-substituted indole-3-glyoxylamide compounds having anti-tumor action
IL139941A0 (en) 1999-12-02 2002-02-10 Pfizer Prod Inc Use of prostaglandin agonists to treat erectile dysfunction or impotence
WO2001045674A1 (en) 1999-12-20 2001-06-28 Cocensys, Inc. Process for producing nanometer particles by fluid bed spray-drying
DE19962300A1 (de) 1999-12-23 2001-06-28 Asta Medica Ag Substituierte N-Benzyl-Indol-3-yl-glyoxylsäure-Derivate mit Antitumorwirkung
US6306911B1 (en) 2000-02-07 2001-10-23 Ortho-Mcneil Pharmaceutical, Inc. Substituted amino acids as neutral sphingomyelinase inhibitors
AU2001238424A1 (en) 2000-02-18 2001-08-27 Merck And Co., Inc. Inhibitors of prenyl-protein transferase
WO2001060369A1 (en) 2000-02-18 2001-08-23 Merck & Co., Inc. Inhibitors of prenyl-protein transferase
DE10023484A1 (de) 2000-05-09 2001-11-22 Schering Ag Anthranylamide und deren Verwendung als Arzneimittel
CN1224423C (zh) 2000-07-17 2005-10-26 山之内制药株式会社 改善口服吸收的医药组合物
US7115279B2 (en) 2000-08-03 2006-10-03 Curatolo William J Pharmaceutical compositions of cholesteryl ester transfer protein inhibitors
US6576644B2 (en) 2000-09-06 2003-06-10 Bristol-Myers Squibb Co. Quinoline inhibitors of cGMP phosphodiesterase
WO2002022584A1 (en) 2000-09-11 2002-03-21 Merck & Co., Inc. Thrombin inhibitors
US6642252B2 (en) 2000-11-07 2003-11-04 Bristol-Myers Squibb Company Acid derivatives useful as serine protease inhibitors
US7037528B2 (en) 2000-12-22 2006-05-02 Baxter International Inc. Microprecipitation method for preparing submicron suspensions
ES2292830T3 (es) 2001-02-21 2008-03-16 Astrazeneca Ab Compuestos heteropoliciclicos y su uso como antagonistas del receptor metabotropico de glutamato.
DE10110749A1 (de) 2001-03-07 2002-09-12 Bayer Ag Substituierte Aminodicarbonsäurederivate
US7034013B2 (en) 2001-03-20 2006-04-25 Cydex, Inc. Formulations containing propofol and a sulfoalkyl ether cyclodextrin
US7459470B2 (en) 2001-05-08 2008-12-02 Schering Ag N-oxide anthranylamide derivatives and their use as medicaments
CZ20033341A3 (cs) 2001-06-21 2004-10-13 Pfizeráproductsáinc Samoemulgující se kompozice inhibitorů přenosového proteinu cholesterylesteru
MXPA03011922A (es) 2001-06-22 2004-03-26 Pfizer Prod Inc Composiciones farmaceuticas que contienen un dispersion solida de un farmaco ligeramente soluble en una matriz y plimero mejorador de solubilidad.
AU2002309172A1 (en) 2001-06-22 2003-01-08 Pfizer Products Inc. Pharmaceutical compositions containing polymer and drug assemblies
CA2448825C (en) 2001-06-22 2009-08-11 Pfizer Products Inc. Pharmaceutical compositions of adsorbates of amorphous drug
EP1269994A3 (en) 2001-06-22 2003-02-12 Pfizer Products Inc. Pharmaceutical compositions comprising drug and concentration-enhancing polymers
WO2003030909A1 (en) 2001-09-25 2003-04-17 Bayer Pharmaceuticals Corporation 2- and 4-aminopyrimidines n-substtituded by a bicyclic ring for use as kinase inhibitors in the treatment of cancer
US6713499B2 (en) 2001-12-12 2004-03-30 Hoffman-La Roche Inc. 7-Amino-benzothiazole derivatives
EP1474144B1 (en) 2002-02-01 2008-08-06 Pfizer Products Inc. Controlled release pharmaceutical dosage forms of a cholesteryl ester transfer protein inhibitor
AR038375A1 (es) 2002-02-01 2005-01-12 Pfizer Prod Inc Composiciones farmaceuticas de inhibidores de la proteina de transferencia de esteres de colesterilo
GB0208280D0 (en) 2002-04-10 2002-05-22 Glaxo Group Ltd Novel compounds
US20040053842A1 (en) 2002-07-02 2004-03-18 Pfizer Inc. Methods of treatment with CETP inhibitors and antihypertensive agents
US7071210B2 (en) 2002-07-02 2006-07-04 Pfizer Inc. CETP inhibitors in combination with antihypertensive agents and uses thereof
NZ532494A (en) 2002-08-30 2006-03-31 Japan Tobacco Inc Dibenzylamine compound and medicinal use thereof
BR0317521A (pt) 2002-12-20 2005-11-16 Pfizer Prod Inc Formas de dosagem compreendendo um inibidor da cetp e um inibidor da redutase hmg-coa
GB0303683D0 (en) 2003-02-18 2003-03-19 Prolysis Ltd Antimicrobial agents
WO2004078128A2 (en) 2003-02-28 2004-09-16 Bayer Pharmaceuticals Corporation Substituted pyridine derivatives useful in the treatment of cancer and other disorders
EP1601351A1 (en) 2003-03-04 2005-12-07 Pfizer Products Inc. Use of ep2 selective receptor agonists in medical treatment
ATE383335T1 (de) 2003-06-11 2008-01-15 Lilly Co Eli 3-amino-pyrrolidine als inhibitoren der monoamin- wiederaufnahme
RU2006102981A (ru) 2003-08-04 2007-09-20 Пфайзер Продактс Инк. (Us) Лекарственные формы, обеспечивающие контролируемое высвобождение ингибиторов белка-переносчика эфиров холестерина и немедленное высвобождение ингибиторов hmg-соа-редуктазы
US7276610B2 (en) 2003-08-27 2007-10-02 Janssen Pharaceutica, Nv Aryl piperidine amides
CN103330703A (zh) 2003-09-26 2013-10-02 日本烟草产业株式会社 抑制残余脂蛋白产生的方法
PT1732933E (pt) 2004-03-26 2008-10-20 Lilly Co Eli Compostos para o tratamento da dislipidémia
UA90269C2 (ru) 2004-04-02 2010-04-26 Мицубиси Танабе Фарма Корпорейшн Тетрагидрохинолиновые производные и способ их получения
TWI345568B (en) 2004-04-02 2011-07-21 Mitsubishi Tanabe Pharma Corp Tetrahydronaphthyridine derivatives and a process for preparing the same
EP1737811B1 (en) 2004-04-13 2016-08-10 Merck Sharp & Dohme Corp. Cetp inhibitors
PE20061124A1 (es) 2004-11-23 2006-10-13 Pfizer Prod Inc Compuestos y derivados de dibencil amina
CN103102303B (zh) * 2004-12-31 2015-10-28 雷迪博士实验室有限公司 作为cetp抑制剂的苄胺衍生物
US8604055B2 (en) * 2004-12-31 2013-12-10 Dr. Reddy's Laboratories Ltd. Substituted benzylamino quinolines as cholesterol ester-transfer protein inhibitors
WO2006129167A1 (en) 2005-05-31 2006-12-07 Pfizer Products Inc. PHARMACEUTICAL COMPOSITIONS OF CHOLESTERYL ESTER TRANSFER PROTEIN INHIBITORS AND HMG-CoA REDUCTASE INHIBITORS
CN101448397B (zh) * 2005-12-28 2013-04-24 雷迪博士实验室有限公司 选择性的苄胺衍生物和其作为胆固醇酯转运蛋白抑制剂的应用
PE20071025A1 (es) * 2006-01-31 2007-10-17 Mitsubishi Tanabe Pharma Corp Compuesto amina trisustituido
WO2007092642A2 (en) 2006-02-09 2007-08-16 Merck & Co., Inc. Polymer formulations of cetp inhibitors
KR101172120B1 (ko) 2006-05-10 2012-08-10 노파르티스 아게 Cetp 억제제로서의 바이시클릭 유도체
US7790737B2 (en) 2007-03-13 2010-09-07 Kowa Company, Ltd. Substituted pyrimidine compounds and their utility as CETP inhibitors
JP4834699B2 (ja) * 2007-07-30 2011-12-14 田辺三菱製薬株式会社 医薬組成物
CN101418397A (zh) * 2008-12-02 2009-04-29 西北有色金属研究院 一种TiB2强化的MgAlB14超硬材料的制备方法

Also Published As

Publication number Publication date
JP2014527997A (ja) 2014-10-23
EP2760864A1 (en) 2014-08-06
CA2850022A1 (en) 2013-04-04
CN103958511A (zh) 2014-07-30
KR20140082689A (ko) 2014-07-02
EP2760864B1 (en) 2018-01-24
JP6140168B2 (ja) 2017-05-31
US9000007B2 (en) 2015-04-07
WO2013046045A1 (en) 2013-04-04
NZ622698A (en) 2016-09-30
AU2012313971A1 (en) 2014-05-01
IN2014CN02290A (cg-RX-API-DMAC7.html) 2015-06-19
HK1197238A1 (en) 2015-01-09
MX2014003660A (es) 2014-10-17
CA2850022C (en) 2018-05-01
US20140288072A1 (en) 2014-09-25
AU2012313971A8 (en) 2014-06-19
AU2012313971B2 (en) 2016-09-29
KR101803866B1 (ko) 2017-12-04

Similar Documents

Publication Publication Date Title
MD20140063A2 (ro) Derivaţi de acid benzotiazol-6-il acetic şi utilizarea acestora pentru tratarea unei infecţii HIV
MX2014015158A (es) Derivados de piridinona y piridazinona.
PH12015501452A1 (en) Novel quinolone derivatives
IN2014CN03073A (cg-RX-API-DMAC7.html)
MX2014000341A (es) Novedosos derivados de trifluoro-metil-oxadiazol y su uso en el tratamiento de enfermedades.
IN2014DN09352A (cg-RX-API-DMAC7.html)
UA111770C2 (uk) Інгібітори бромдомену
MX2014004479A (es) Derivados de oxazina novedosos y su uso en el tratamiento de enfermedades.
IN2014DN09348A (cg-RX-API-DMAC7.html)
EA201391127A1 (ru) C-17 и c-3 модифицированные тритерпеноиды с ингибиторной активностью созревания вич
UA109010C2 (en) Morpholino pyrividines and their use in therapy
EA201391098A1 (ru) C-28-амины c-3-модифицированных производных бетулиновой кислоты в качестве ингибиторов созревания вич
MX2015010354A (es) Derivados de acido betulinico modificados con aquilo c-3 y alquenilo utiles en el tratamiento de virus de inmunodeficiencia humana (vih).
PH12014501283A1 (en) 4`-azido, 3``-fluoro substituted nucleoside derivatives as inhibitors of hcv rna replication
PH12012500622A1 (en) Compounds for the treatment of dyslipidemia and related diseases
PH12013500007A1 (en) Piperidine derivatives and their use for the treatment of metabolic disorders
EA201390984A1 (ru) Гетероциклические соединения, подходящие для лечения дислипидемии
EA201390008A1 (ru) Новые ариламидные производные, обладающие антиандрогенными свойствами
MX2012002369A (es) Formas de anhidrato de un derivado de piridina.
BR112013019160A2 (pt) novos compostos, composição farmacêutica, uso, processos e métodos
IN2014DN09347A (cg-RX-API-DMAC7.html)
MX352074B (es) Derivados de 5-bencilaminometil-6-aminopirazolo [3,4-b] piridina como inhibidores de proteina de transferencia de ester de colesterilo (cetp) utiles para el tratamiento de aterosclerosis.
HK1210162A1 (en) Pyrimidinone derivatives as antimalarial agents
MX2015001657A (es) Compuestos de cianopirazol substituidos con receptores de acido lisofosfatidico (lpar).
WO2012019428A8 (zh) 二苯甲醇类衍生物、其制备方法及其在医药上的应用

Legal Events

Date Code Title Description
FG Grant or registration